EB3 Cells

The EB3 cell line is a human Burkitt lymphoma model that was originally derived from a young child with a maxillary tumor in Uganda. It is one of several established Burkitt lymphoma cell lines created during early investigations into the immunological and biological characteristics of this malignancy. Notably, EB3 cells express strong membrane immunofluorescence reactivity when probed with serum from Burkitt lymphoma patients in remission following chemotherapy, suggesting the presence of tumor-associated antigens on their surface. This reactivity is likely mediated by IgG-class antibodies, as shown using fluorescein-conjugated anti-IgG reagents. EB3 was found to react strongly alongside other Burkitt-derived lines such as Jijoye, B35M, and SL1, whereas certain other Burkitt lines, like Raji, did not show similar reactivity under the same conditions.

EB3 cells were among those used in early comparative studies to distinguish between tumor-specific and isoantigenic responses in Burkitt lymphoma. These investigations demonstrated that sera from some patients—particularly those in complete remission—could selectively recognize Burkitt lymphoma cells over normal bone marrow or lymphocytes from the same donor, indicating tumor-specific immunogenic markers. Additionally, EB3 cells displayed morphological and immunophenotypic features consistent with large lymphoblast-like Burkitt lymphoma cells, which tend to exhibit bright granular membrane staining when exposed to reactive serum. This historic immunological profiling of EB3 helped to establish the groundwork for later studies exploring tumor-specific antigens in lymphoid malignancies.